首页> 外文期刊>Regulatory Affairs Journal- Devices >Advancing regenerative medicine in the US requires regulatory change
【24h】

Advancing regenerative medicine in the US requires regulatory change

机译:在美国,再生医学的发展需要法规的改变

获取原文
获取原文并翻译 | 示例
           

摘要

Americans have been engaged in a detailed and politically charged debate about healthcare reform for the past few years, but there has been surprisingly little discussion about ways new technologies such as regenerative medicine can improve clinical care and reduce spending, These innovative technologies may represent our best hope for dealing with the challenges - primarily due to an ageing population - that lie ahead. As a cross-cutting technology, regenerative medicine will support the major therapeutic approaches such as small molecule drugs, complex biologicals, medical devices and diagnostics. Indeed, regenerative medicine products are already available to treat a variety of conditions, including chronic wounds, cartilage defects and diabetic foot ulcers, while products addressing many more conditions are advancing in clinical trials.
机译:在过去的几年中,美国人一直在就医疗改革进行详细的政治辩论,但令人惊讶的是,关于再生医学等新技术如何改善临床护理和减少支出的讨论很少,这些创新技术可能代表了我们最好的希望能够应对即将到来的挑战-主要是由于人口老龄化。作为一种跨领域技术,再生医学将支持主要的治疗方法,例如小分子药物,复杂的生物制剂,医疗设备和诊断方法。实际上,再生医学产品已经可用于治疗多种疾病,包括慢性伤口,软骨缺损和糖尿病足溃疡,而针对更多疾病的产品正在临床试验中不断发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号